New pill shows promise for long-term rheumatoid arthritis control

NCT ID NCT04049448

Completed Disease control Sponsor: Abivax S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of a daily pill called ABX464 in 40 adults with moderate to severe rheumatoid arthritis. Participants had already completed 12 weeks of treatment in an earlier study. The goal was to see if ABX464 can help keep the disease under control over many months. The study focused on tracking side effects and measuring how well the drug maintained low disease activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

CHR d'Orléans

Orléans, France
CHU DE MONTPELLIER - Hôpital Lapeyronie

Montpellier, France
CHU de Brest - Hôpital Cavale Blanche

Brest, France
CMed Rehabilitációs és Diagnosztikai Központ

Székesfehérvár, Hungary
CRU Hungary Ltd.

Miskolc, Hungary
ClinicMed Daniluk, Nowak Sp. J.

Bialystok, Poland
Cliniques Universitaires Saint-Luc

Brussels, Belgium
Complex Medical Centre - Déli Klinika

Budapest, Hungary
Medyczne Centrum Hetmańska

Poznan, Poland
NZOZ Lecznica MAK-MED S.C.

Nadarzyn, Poland
National Institute of Geriatrics

Warsaw, Poland
Pratia MCM

Krakow, Poland
UZ Gent

Ghent, Belgium
Zespół Poradni Specjalistycznych REUMED

Lublin, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.